KR102606838B1 - Antioxidative and antiinflammatory compostion comprising the extract of plant root - Google Patents
Antioxidative and antiinflammatory compostion comprising the extract of plant root Download PDFInfo
- Publication number
- KR102606838B1 KR102606838B1 KR1020230008928A KR20230008928A KR102606838B1 KR 102606838 B1 KR102606838 B1 KR 102606838B1 KR 1020230008928 A KR1020230008928 A KR 1020230008928A KR 20230008928 A KR20230008928 A KR 20230008928A KR 102606838 B1 KR102606838 B1 KR 102606838B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- root
- cream
- pack
- cosmetic composition
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 22
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 title abstract description 44
- 241000196324 Embryophyta Species 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 30
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 28
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 28
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 23
- 244000281702 Dioscorea villosa Species 0.000 claims abstract description 21
- 241000228212 Aspergillus Species 0.000 claims abstract description 10
- 240000005528 Arctium lappa Species 0.000 claims abstract 2
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 2
- 210000004209 hair Anatomy 0.000 claims description 91
- 239000000243 solution Substances 0.000 claims description 24
- 239000006071 cream Substances 0.000 claims description 23
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 239000006210 lotion Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 9
- 230000035764 nutrition Effects 0.000 claims description 9
- 239000006260 foam Substances 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 230000001256 tonic effect Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 241000195940 Bryophyta Species 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 239000000118 hair dye Substances 0.000 claims description 3
- 239000008266 hair spray Substances 0.000 claims description 3
- 239000004922 lacquer Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 241000736199 Paeonia Species 0.000 description 28
- 241000208843 Arctium Species 0.000 description 26
- 235000006708 antioxidants Nutrition 0.000 description 21
- 238000000605 extraction Methods 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000011506 response to oxidative stress Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 229940063333 burdock root extract Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- -1 patches Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940119214 rehmannia glutinosa root extract Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 추출물 중 1종 이상을 포함하는 조성물로서, 항산화 및 항염증 효능이 우수하다.The present invention is a composition containing one or more of extracts of peony root, burdock root, Rehmannia glutinosa root, yam root, and Aspergillus root extract, and has excellent antioxidant and anti-inflammatory effects.
Description
본 발명은 식물 뿌리 추출물을 포함하는 항산화 및 항염증용 조성물에 관한 것이다.The present invention relates to an antioxidant and anti-inflammatory composition containing plant root extract.
피부는 외부환경으로부터 우리 몸을 보호하는 일차적인 기능과 미용적인 기능을 가지고 있다. Skin has a primary function of protecting our body from the external environment and a cosmetic function.
피부의 산화 스트레스 및 염증 반응은 피부에서 발생하는 다양한 질환들의 원인으로 알려져 있다. 산화 스트레스 및 염증 반응에 의해 피부 노화, 자극, 색소 침착, 장벽 기능 저하, 피부 건조 등과 같은 다양한 문제들이 야기될 수 있기 때문에, 피부의 항산화 및 항염증 기능은 건강한 피부를 위해 가장 기본적으로 갖춰져야 할 필요가 있다. 피부의 산화 스트레스 및 염증 반응은 다양한 내인적 또는 외인적 요인에 의해 발생할 수 있으며, 우리가 일상 생활에서 쉽게 노출될 수 있는 자외선 및 미세먼지 등에 의해서도 쉽게 발생한다.Oxidative stress and inflammatory reactions in the skin are known to be the cause of various diseases that occur in the skin. Since oxidative stress and inflammatory reactions can cause various problems such as skin aging, irritation, pigmentation, decreased barrier function, and skin dryness, antioxidant and anti-inflammatory functions of the skin are the most basic necessities for healthy skin. There is. Oxidative stress and inflammatory reactions in the skin can be caused by various endogenous or exogenous factors, and are also easily caused by ultraviolet rays and fine dust that we can easily be exposed to in our daily lives.
이러한 피부를 청결하게 하거나 아름답게 표현하는 미적 기능 및 유해 환경으로부터 피부를 보호하는 방어기능을 그 목적으로 하여 화장품을 사용한다.Cosmetics are used for the aesthetic function of cleansing or beautifying the skin and the defensive function of protecting the skin from harmful environments.
그러나, 피부를 보호하고 미화 청결을 위한 목적으로 다양하게 사용되는 피부 외용 제품들에 있어서, 사용이 불가피 하지만 피부 보호 목적과는 상이한 성분들, 예컨대 계면 활성제, 방부제, 향료, 자외선 차단제, 색소, 기능성 원료 등은 피부에 여러 가지 부작용을 발생시키고 있다. 특히 미백, 주름 개선, 각질제거 등을 목적으로 하는 기능성 제품에 함유되는 AHA(알파하이드록시산), 레티놀, 알부틴 등의 성분들은 피부 트러블을 일으키는 주된 원인으로 작용하고 있다.However, in various external skin products used for the purpose of protecting the skin and beautifying and cleansing, the use of ingredients that are unavoidable but different from the purpose of skin protection, such as surfactants, preservatives, fragrances, sunscreens, pigments, and functional ingredients, is unavoidable. Raw materials cause various side effects on the skin. In particular, ingredients such as AHA (alpha hydroxy acid), retinol, and arbutin contained in functional products for whitening, wrinkle improvement, and exfoliation are the main causes of skin problems.
항산화와 관련된 산소는 전자배열에 따라 전자를 획득하기 쉬운 상태가 되어 강력한 산화제가 될 수 있는데, 산소와 관련된 인체내 독성물질을 활성산소종(ROS: reactive oxygen species)이라고 한다. 이러한 ROS의 종류로는 수퍼옥사이드 (superoxide), 하이드록실(hydroxyl), 페록실(peroxyl), 알콕실(alkoxyl), 하이드로페록실(hydroperoxyl)과 같은 자유라디칼(free radical)과 히드로젠페록사이드(hydrogenperoxide), 오존(ozone), 일중항 산소(singlet oxygen), 퍼옥시나이트라이트(peroxinitrite) 등과 같은 비(非)자유라디칼(non free radical)이 있다.Oxygen, which is related to antioxidants, can easily acquire electrons depending on its electron configuration and can become a powerful oxidizing agent. Oxygen-related toxic substances in the human body are called reactive oxygen species (ROS). Types of these ROS include free radicals such as superoxide, hydroxyl, peroxyl, alkoxyl, and hydroperoxyl, and hydrogen peroxide ( There are non-free radicals such as hydrogenperoxide, ozone, singlet oxygen, and peroxinitrite.
자유라디칼은 세포의 기본적인 대사과정(미토콘드리아에서의 에너지 생산 과정 중 전자 전달계의 작용, 백혈구의 식작용 등)으로 꾸준히 생산되고 있을 뿐만 아니라, 자외선, 흡연, 스트레스, 공해물질 등 여러 원인에 의해서 인체에 존재하고 있다.Free radicals are not only continuously produced through the basic metabolic processes of cells (action of the electron transport system during the energy production process in mitochondria, phagocytosis of white blood cells, etc.), but also exist in the human body due to various causes such as ultraviolet rays, smoking, stress, and pollutants. I'm doing it.
1956년 덴함 하르만(Denham Harman)은 유기호흡과정에서 생산되는 자유라디칼이 산화적 손상을 축적시킴으로서 노화를 야기하고 죽음을 초래한다는 노화와 자유기에 관한 이론을 제시하였다. 그 이후 반응성이 강한 자유라디칼은 심장질환, 암, 백내장 등 60여종 이상의 질병과도 밀접한 관련이 있으며 노화에서 특징적으로 나타나는 세포의 구조와 기능의 변화를 초래하는 중요한 인자임이 여러 실험을 통해 밝혀지고 있어 노화 관련 변화의 특징인 생리학적 쇠퇴의 대부분이 자유라디칼에 의한 세포 손상이라는 이론이 점차 설득력을 얻고 있다.In 1956, Denham Harman proposed a theory on aging and free radicals that states that free radicals produced during organic respiration accumulate oxidative damage, causing aging and death. Since then, highly reactive free radicals are closely related to more than 60 types of diseases, including heart disease, cancer, and cataracts, and have been revealed through various experiments to be an important factor in causing changes in cellular structure and function that are characteristic of aging. The theory that most of the physiological decline that characterizes age-related changes is caused by cellular damage caused by free radicals is increasingly gaining ground.
이러한 산화적 스트레스로부터 인체를 보호하기 위해 식용 혹은 약용식물로부터 강력하고 사람의 피부에 안전한 천연 항산화제를 분리, 동정, 개발하려는 많은 연구가 진행되고 있으나 실제 제품에 적용될 경우 여러 작용에 의해 쉽게 산화되어 버리는 문제가 있으며, 다양한 기능을 갖는 항산화 물질을 동시에 사용하여 효능을 증대시키더라도 자유라디칼 소거 능력의 지속성이 짧은 문제점이 있다.In order to protect the human body from such oxidative stress, much research is being conducted to isolate, identify, and develop natural antioxidants from edible or medicinal plants that are powerful and safe for human skin. However, when applied to actual products, they are easily oxidized due to various effects. There is a problem of discarding it, and even if the efficacy is increased by using antioxidant substances with various functions at the same time, there is a problem that the free radical scavenging ability is short-lived.
한편, 염증은 체내의 자극에 의해 변화된 손상 부위를 재생하려는 기전인데, 지속적인 염증 반응은 점막 손상을 촉진시켜 결과적으로 통증, 부종, 발적, 발열 등을 일으켜 기능 장애를 유발한다. 대식세포는 다양한 숙주반응을 통한 항상성 유지에 관여하는 것으로 알려져 있는데, 염증반응 시에는 유도성 산화질소 합성효소 (inducible nitric oxide synthase)에 의해 만들어지는 산화질소(nitric oxide)와 사이클로옥시제나아제 (cyclooxygenase)-2에 의해서 과량 만들어지는 프로스타글란딘(prostaglandin) E2 등과 같은 염증 촉진 인자들이 생성된다. 또한, 리포폴리사카라이드(lipopolysaccharide: LPS)에 의해 유발된 세포에서 염증매개 물질인 튜머 네크로시스 팩터(tumor necrosis factor)-α, 인터루킨(interleukin)-6 및 인터루킨(interleukin)-1β와 같은 사이토카인을 생산하여 다양한 염증반응을 매개한다.Meanwhile, inflammation is a mechanism that attempts to regenerate damaged areas that have changed due to stimulation within the body. A continuous inflammatory response promotes mucosal damage, resulting in pain, swelling, redness, and fever, resulting in functional impairment. Macrophages are known to be involved in maintaining homeostasis through various host reactions. During inflammatory reactions, nitric oxide and cyclooxygenase are produced by inducible nitric oxide synthase. Inflammatory factors such as prostaglandin E2, which are produced in excess by )-2, are produced. In addition, in cells induced by lipopolysaccharide (LPS), cytokines such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, which are inflammatory mediators, are produced. It produces and mediates various inflammatory responses.
상기와 같은 이유로 피부 자극 및 염증의 생성을 줄일 수 있는 방법에 관한 연구가 활발히 진행되고 있으며, 항염제제로 사용되는 물질로 비스테로이드 계통의 벤지다민, 인도메타신, 이부프로펜 등이 있으며, 스테로이드 계통의 덱사메타손, 하이드로코티존 등이 있다. (Leung Y.F. et al., Mol Vis. Sep 5;9:425-39 (2003), Rocksen D. et al., Clin Exp Immunol. 122(2):249-56 (2000), Endo Y. et al., Res Commun Chem Pathol Pharmacol. 33(2):195-206 (1981), FAVOUR C.B. et al., Med Bull. 6(1):15-8 (1958), Sato S. et al., J Osaka Dent Univ.1(1):37-49 (1967))For the above reasons, research is being actively conducted on methods to reduce skin irritation and inflammation. Substances used as anti-inflammatory agents include non-steroidal benzydamine, indomethacin, and ibuprofen, and steroidal dexamethasone. , hydrocortisone, etc. (Leung Y.F. et al., Mol Vis. Sep 5;9:425-39 (2003), Rocksen D. et al., Clin Exp Immunol. 122(2):249-56 (2000), Endo Y. et al. ., Res Commun Chem Pathol Pharmacol. 33(2):195-206 (1981), FAVOUR C.B. et al., Med Bull. 6(1):15-8 (1958), Sato S. et al., J Osaka Dent Univ.1(1):37-49 (1967))
그런데, 상기의 물질들은 피부에 사용할 수 없거나 사용량이 제한된 경우가 대부분이며, 특히 스테로이드 계통의 경우 피부 위축, 불면, 불안 등의 부작용을 동반하고 있다.However, in most cases, the above substances cannot be used on the skin or the amount of use is limited, and especially in the case of steroids, they are accompanied by side effects such as skin atrophy, insomnia, and anxiety.
따라서, 피부에 안전성이 우수한 천연 식물로부터 항산화 및 항염증 효능을 갖는 물질을 발굴할 필요성이 증대되고 있다.Therefore, the need to discover substances with antioxidant and anti-inflammatory effects from natural plants that are safe for the skin is increasing.
특히 식물은 사용하는 약용 부위에 따라 다른 효능을 보이기도 하고 효능의 차이를 보이기도 한다. In particular, plants may show different effects or show differences in efficacy depending on the medicinal part used.
일례로, 특허문헌 1은 건선 치료용 조성물로서 목단피, 생지, 우방자 등을 개시하고 있으나, 식물 뿌리 추출물의 항산화 및 항염증 효과에 대한 개시가 없고, 특허문헌 2 내지 5는 식물 추출물로서 항산화 관련 효능을 개시하고 있을 뿐이다.For example, Patent Document 1 discloses psoriasis treatment compositions such as dandelion bark, raw fat, and soybean sprouts, but there is no disclosure about the antioxidant and anti-inflammatory effects of plant root extracts, and Patent Documents 2 to 5 disclose antioxidant-related effects as plant extracts. is just starting.
본 발명은 항산화 및 항염증 효능을 갖는 조성물을 제공하고자 한다.The present invention seeks to provide a composition having antioxidant and anti-inflammatory effects.
또한, 본 발명은 상기 조성물을 포함하는 화장료 조성물을 제공하고자 한다.Additionally, the present invention seeks to provide a cosmetic composition containing the above composition.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 추출물 중 1종 이상을 포함하는 것이 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention preferably includes one or more of extracts of peony root, burdock root, Rehmannia glutinosa root, yam root, and Aspergillus root extract.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리 및 우엉 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root and burdock root.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리 및 지황 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root, burdock root and Rehmannia glutinosa root.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리, 지황 뿌리 및 참마 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root, burdock root, Rehmannia glutinosa root and yam root.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root, burdock root, Rehmannia glutinosa root, yam root and Aspergillus root.
상기 조성물이 에어로졸, 액체, 용액, 젤, 페이스트, 크림, 연고, 폼 및 분말 중 어느 하나의 제형으로 되는 것이 바람직하다.The composition is preferably in the form of any one of aerosol, liquid, solution, gel, paste, cream, ointment, foam, and powder.
상기 조성물이 팩, 밴드 또는 패치 중 어느 하나에 포함되는 것이 바람직하다.It is preferable that the composition is included in any one of a pack, band, or patch.
상기 팩은 국소형 패치, 시트타입, 거즈타입, 크림타입 및 젤타입 중 어느 하나인 것이 보다 바람직하다.It is more preferable that the pack is any one of topical patch, sheet type, gauze type, cream type, and gel type.
상기 조성물이 약학적 조성물 또는 화장료 조성물 중 어느 하나인 것이 바람직하다.It is preferable that the composition is either a pharmaceutical composition or a cosmetic composition.
상기 화장료 조성물이 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 및 헤어스프레이를 포함하는 군에서 선택되는 제형인 것이 바람직하다.The cosmetic composition includes hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, hair wax, and hair aerosol. , hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair dryer, hair preservation treatment, hair dye, hair waving agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer, hair moisturizer, It is preferable that it is a formulation selected from the group including hair mousse and hair spray.
상기 약학적 조성물이 정제, 캅셀제, 주사제, 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제를 포함하는 군에서 선택되는 제형인 것이 바람직하다.It is preferable that the pharmaceutical composition is a formulation selected from the group including tablets, capsules, injections, creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents.
본 발명은 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 추출물 중 1종 이상을 포함하는 조성물로서, 항산화 및 항염증 효능이 우수하다.The present invention is a composition containing one or more of extracts of peony root, burdock root, Rehmannia glutinosa root, yam root, and Aspergillus root extract, and has excellent antioxidant and anti-inflammatory effects.
도 1은 본 발명에 따른 조성물의 세포 내 활성산소종 생성 저해능 측정 결과를 개략적으로 도시한 것이다.
도 2는 본 발명에 따른 조성물의 산화 질소 생성 저해능 측정 결과를 개략적으로 도시한 것이다.
도 3 및 도 4는 본 발명에 따른 조성물의 전염증성 사이토카인 발현 억제 측정 결과를 개략적으로 도시한 것이다.
도 5는 본 발명에 따른 조성물의 염증 유도형 효소 발현 억제 측정 결과를 개략적으로 도시한 것이다.Figure 1 schematically shows the results of measuring the ability of the composition according to the present invention to inhibit intracellular reactive oxygen species production.
Figure 2 schematically shows the results of measuring the nitric oxide production inhibition ability of the composition according to the present invention.
Figures 3 and 4 schematically show the results of measuring inhibition of pro-inflammatory cytokine expression by the composition according to the present invention.
Figure 5 schematically shows the results of measuring the inhibition of inflammation-inducing enzyme expression by the composition according to the present invention.
이하, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시형태를 들어 상세히 설명한다. 본 발명의 실시형태는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 더욱 완전하게 설명하기 위해서 제공되는 것이다. 따라서, 본 발명의 실시형태는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 이하 설명하는 실시형태로 한정되는 것은 아니다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement it. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art. Accordingly, the embodiments of the present invention may be modified into various other forms, and the scope of the present invention is not limited to the embodiments described below.
본 발명의 명세서 전체에서, 어떤 부분이 어떤 구성요소를 “포함”한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함하는 것을 의미한다.Throughout the specification of the present invention, when a part “includes” a certain component, this means that it does not exclude other components but further includes other components, unless specifically stated to the contrary.
본 발명의 명세서 전체에서, 어떤 단계가 다른 단계와 “상에” 또는 “전에” 위치하고 있다고 할 때, 이는 어떤 단계가 다른 단계와 직접적 시계열적인 관계에 있는 경우뿐만 아니라, 각 단계 후의 혼합하는 단계와 같이 두 단계의 순서에 시계열적 순서가 바뀔 수 있는 간접적 시계열적 관계에 있는 경우와 동일한 권리를 포함할 수 있다.Throughout the specification of the present invention, when a step is said to be located “on” or “before” another step, this means not only when a step is in a direct time-series relationship with another step, but also when a step is in a direct time-series relationship with the other step, as well as a mixing step after each step. Likewise, the order of two steps can include the same rights as in the case of an indirect time-series relationship in which the time-series order can be changed.
본 발명의 명세서 전체에서 사용되는 정도의 용어 “약”, “실질적으로” 등은 언급된 의미에 고유한 제조 및 물질 허용 오차가 제시될 때 그 수치에서 또는 그 수치에 근접한 의미로 사용되고, 본 발명의 이해를 돕기 위해 정확하거나 절대적인 수치가 언급된 개시 내용을 비양심적인 침해자가 부당하게 이용하는 것을 방지하기 위해 사용된다. 본원 명세서 전체에서 사용되는 용어 “~(하는) 단계” 또는 “~의 단계”는 “~를 위한 단계”를 의미하지 않는다.The terms "about", "substantially", etc. used throughout the specification of the present invention are used to mean at or close to that value when manufacturing and material tolerances inherent in the stated meaning are presented, and the present invention Precise or absolute figures are used to aid understanding and to prevent unscrupulous infringers from taking unfair advantage of the disclosure. The term “step of” or “step of” used throughout the specification does not mean “step for.”
본 발명에 따른 항산화 및 항염증 조성물은 식물의 꽃, 잎, 열매, 줄기 등이 아니라 뿌리 추출물인 것이 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention is preferably a root extract rather than a plant flower, leaf, fruit, stem, etc.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 추출물 중 1종 이상을 포함하는 것이 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention preferably includes one or more of extracts of peony root, burdock root, Rehmannia glutinosa root, yam root, and Aspergillus root extract.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리 및 우엉 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root and burdock root.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리 및 지황 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root, burdock root and Rehmannia glutinosa root.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리, 지황 뿌리 및 참마 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root, burdock root, Rehmannia glutinosa root and yam root.
본 발명에 따른 항산화 및 항염증 조성물은 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 추출물을 포함하는 것이 보다 바람직하다.The antioxidant and anti-inflammatory composition according to the present invention more preferably contains extracts of peony root, burdock root, Rehmannia glutinosa root, yam root and Aspergillus root.
상기 모란은, 목단(牧丹)이라고도 한다. 높이 2m이며 각처에서 재배하고 있다. 가지는 굵고 털이 없다. 잎은 3겹으로 되어 있고 작은 잎은 달걀모양이며 2∼5개로 갈라진다. 잎 표면은 털이 없고 뒷면은 잔털이 있으며 흔히 흰빛이 돈다. 꽃은 양성으로 5월에 홍색으로 피고 지름 15cm 이상이며 꽃턱이 주머니처럼 되어 씨방을 둘러싼다. 꽃받침조각은 5개이고 꽃잎은 8개 이상이며 크기와 형태가 같지 않고 달걀을 거꾸로 세운 모양으로서 가장자리에 불규칙하게 깊이 패어 있는 모양이 있다. 수술은 많고 암술은 2∼6개로서 털이 있다. 열매는 9월에 익고 내봉선(內縫線)에서 터져 종자가 나오며, 종자는 둥글고 흑색이다. 많은 재배품종이 있으며 뿌리껍질을 소염·두통·요통·건위·지혈 등에 쓴다. The above peony is also called Mokdan (牧丹). It is 2m tall and is grown in various places. The branches are thick and hairless. The leaves are three-layered and the small leaves are egg-shaped and split into 2 to 5 pieces. The surface of the leaf is hairless and the back side has fine hairs and is often whitish. The flowers are bisexual, bloom red in May, are over 15cm in diameter, and have a pouch-like flower stamen that surrounds the ovary. There are 5 sepals and more than 8 petals, and the size and shape are not the same, and are shaped like an upside-down egg, with deep irregular grooves on the edges. There are many stamens and 2 to 6 pistils with hair. The fruit ripens in September and the inner gland bursts to reveal seeds, which are round and black. There are many cultivated varieties, and the root bark is used for anti-inflammatory, headache, back pain, stomach upset, and hemostasis.
상기 우엉은 높이 50∼150cm이다. 곧은뿌리가 30∼60cm 자라고 끝에서 줄기가 나온다. 뿌리에 달린 잎은 무더기로 나오고 잎자루가 길다. 줄기에서는 어긋나며 심장 모양이다. 겉면은 짙은 녹색이지만 뒷면에 흰 솜털이 빽빽이 나며, 가장자리에 이 모양의 톱니가 있다. 꽃은 7∼8월에 피는데 검은 자줏빛이 돌며, 두화는 가지 끝에 산방꽃차례로 달린다. 총포는 둥글고 포는 바늘 모양이며 끝이 갈고리처럼 생긴다. 꽃은 관상화이고 종자는 검은색이며 관모는 갈색이다. 열매는 수과로서 9월에 익는다. 강건하여 병이 거의 없고 추위에도 매우 강하며 토질을 별로 가리지 않는다. 번식은 종자나 포기나누기로 한다. 유럽 원산의 귀화식물이다. 품종으로는 뿌리가 길고 굵은 농야천과 육질이 좋고 뿌리가 짧은 사천 등이 있다. 조리법은 장아찌를 만들거나 조림을 하여 반찬으로 먹는다. 뿌리에는 이눌린과 약간의 팔미트산이 들어 있다. 유럽에서는 이뇨제와 발한제로 쓰고 종자는 부기가 있을 때 이뇨제로 사용하며, 인후통과 독충(毒蟲)의 해독제로 쓴다. 일본에서 많이 재배하며 유럽, 시베리아, 중국 동북부에 야생한다.The burdock is 50 to 150 cm tall. The tap root grows 30 to 60 cm long, and a stem emerges from the end. The leaves attached to the roots come out in clusters and have long petioles. The stems are alternate and have a heart shape. The outside is dark green, but the back has dense white fluff, and there are teeth shaped like this on the edges. Flowers bloom from July to August and are black-purple, and the flowers hang in corymbs at the ends of branches. The involucre is round, the bracts are needle-shaped, and the ends look like hooks. The flowers are tubular, the seeds are black, and the tubular hairs are brown. The fruit is an achene and ripens in September. It is hardy, rarely suffers from diseases, is very resistant to cold, and is not particularly sensitive to soil type. Propagation is done by seed or by dividing. It is a naturalized plant native to Europe. Varieties include Nongyacheon, which has long and thick roots, and Sacheon, which has good flesh and short roots. The recipe is to make pickled vegetables or stew them and eat them as a side dish. The root contains inulin and some palmitic acid. In Europe, it is used as a diuretic and diaphoretic, and the seeds are used as a diuretic when there is swelling, and as an antidote for sore throats and poisonous insects. It is widely cultivated in Japan and grows wild in Europe, Siberia, and northeastern China.
상기 지황은 현삼과의 지황(Rehmannia glutinosa Liboschitz var. purpurea Makino)의 뿌리를 말려서 만든 약재(한국)로서 중국에서는 지황 말린 것을 생지황(生地黃)이라고 부른다. 지황의 날 것을 물에 담가서 물에 뜨는 것은 천황(天黃), 반쯤 뜨고 반쯤 가라앉는 것은 인황(人黃), 완전히 가라앉는 것은 지황(地黃)이라고 하였다. 이 중에 물에 가라앉는 것이 좋고, 반쯤 가라앉는 것이 다음이고, 물에 뜨는 것은 좋지 않다고 하였다. 지황을 하라고 부르는 것은 가라앉는 것이 귀한 것이므로 하(下)라고 하다가 변한 것이라고 한다. 이 약은 특이한 냄새가 있고 맛은 단 것 같으나 뒤에는 조금 쓰다. 지황은 번조, 갈증, 골증, 소갈증, 토혈, 코피에 쓰이며 열로 인한 피부발진을 치료한다. 약리작용은 혈당강하, 강심, 이뇨, 간기능보호, 항균작용이 보고되었다.The above-mentioned Rehmannia glutinosa is a medicinal material (Korea) made by drying the roots of Rehmannia glutinosa Liboschitz var. purpurea Makino of the Hyeonsam family. In China, dried Rehmannia glutinosa is called raw Rehmannia glutinosa. When the raw rehmannia glutinosa was soaked in water, the one that floated on water was called Cheonhwang (天黃), the half-floating and half-sinking one was called Inhwang (人黃), and the one that sank completely was called Rehmanniae (地黃). Among these, it is said that sinking in water is good, half-sinking is next, and floating is not good. It is said that the reason why it is called Rehmannia glutinosa is because it is precious to sink, so it is said to have changed from being called lower. This medicine has a peculiar smell and tastes sweet, but is a bit bitter afterward. Rehmannia glutinosa is used for fever, thirst, osteoarthritis, hypothermia, hematemesis, and nosebleeds, and treats skin rashes caused by heat. Pharmacological effects have been reported to lower blood sugar level, tonic, diuretic, protect liver function, and antibacterial activity.
상기 참마는 당마라고도 한다. 주로 산지에서 자란다. 원주형의 육질 뿌리에서 줄기가 나와서 다른 물체를 감아 올라간다. 잎은 마주나거나 어긋나고 잎자루가 길며 긴 타원형 또는 삼각형으로 끝이 뾰족하며 밑은 심장저이고 털이 없다. 잎겨드랑이에서 주아(珠芽)가 자란다. 꽃은 단성화로 6∼7월에 피고 수상꽃차례에 달린다. 수꽃이삭은 곧게 서고, 암꽃이삭은 밑으로 처지며 흰색 꽃이 달린다. 수꽃에는 6개씩의 수술과 화피갈래조각 및 1개의 암술이 있고, 암꽃에는 6개의 화피갈래조각과 1개의 암술이 있다. 열매는 삭과로 3개의 날개가 있고 종자에도 막질의 날개가 있다. 뿌리줄기는 식용하며 강장제 및 지사제로도 사용한다.The yam is also called dang yam. It mainly grows in mountainous areas. A stem emerges from a cylindrical fleshy root and wraps itself around another object. The leaves are opposite or alternate, have long petioles, are long oval or triangular, have sharp ends, have a heart base, and are hairless. Flower buds grow in the leaf axils. The flower is a solitary flower that blooms from June to July and hangs on a water inflorescence. The male flower spikes stand upright, and the female flower spikes droop downward and bear white flowers. Male flowers have six stamens, perianth segments, and one pistil, and female flowers have six perianth segments and one pistil. The fruit is a capsule with three wings, and the seeds also have membranous wings. The rhizome is edible and is also used as a tonic and anti-diarrheal agent.
상기 천궁은 중국 원산이며 약용 식물로 재배한다. 높이 30∼60cm이며 속이 비어 있고 가지가 다소 갈라진다. 잎은 어긋나고 2회 3출 깃꼴겹잎이며 갈래조각은 달걀 모양의 바소꼴이고 다소 깊은 톱니가 있다. 뿌리잎과 밑부분의 잎은 긴 잎자루가 있고 밑부분이 잎집으로 되어 줄기를 감싼다. 꽃은 8~9월에 피고 흰색이며 복산형꽃차례를 이룬다. 꽃잎은 5개이고 안쪽으로 말리며 수술은 5개, 암술은 1개이다. 총포와 소총포는 각각 5∼6개이며 줄 모양이다. 열매는 열리지만 성숙하지 않는다. 땅 속에 있는 마디 사이는 길이 5∼10cm, 지름 3∼5cm의 덩어리처럼 생기고 강한 향기가 있다. 진정 ·진통 ·강장 등에 효능이 있어 두통 ·빈혈증 ·부인병 등을 치료하는데 쓴다. 9~11월에 근경을 캐어 잎과 줄기를 제거하고 햇볕에 말린후 3~6g을 달여서 복용하거나, 환제(丸劑)나 산제(散劑)로 하여 사용한다.The above Cheongung is native to China and is cultivated as a medicinal plant. It is 30-60cm high, is hollow, and has somewhat branched branches. The leaves are alternate, pinnately compound leaves with two or three branches, and the forked pieces are egg-shaped and have somewhat deep serrated teeth. The root leaves and lower leaves have long petioles, and the lower part becomes a leaf sheath that surrounds the stem. The flowers bloom from August to September, are white, and form a compound umbel. There are 5 petals, rolled inward, 5 stamens, and 1 pistil. There are 5 to 6 gun and rifle cannons each, shaped like a row. The fruit grows but does not mature. The internodes in the ground look like lumps 5 to 10 cm long and 3 to 5 cm in diameter and have a strong scent. It has sedative, analgesic, and tonic effects and is used to treat headaches, anemia, and gynecological diseases. From September to November, the rhizome is dug up, the leaves and stems are removed, dried in the sun, and 3 to 6 g is boiled and taken or used as a pill or powder.
본 발명에 따른 조성물은 에어로졸, 액체, 용액, 젤, 페이스트, 크림, 연고, 폼 및 분말 중 어느 하나의 제형으로 가능하며, 이에 제한되지 않는다.The composition according to the present invention can be in the form of any one of aerosol, liquid, solution, gel, paste, cream, ointment, foam, and powder, but is not limited thereto.
예를 들어, 로션은 용액과 유사하지만 용액보다 더 진하고 본질적으로 더 완화시키는 경향이 있다. 로션에는 일반적으로 물과 오일이 혼합되어 있으며 용액보다 알코올이 적은 경우가 많다.For example, lotions are similar to solutions, but tend to be thicker and more emollient in nature. Lotions are usually a mixture of water and oil and often contain less alcohol than a solution.
예를 들어, 크림은 거의 같은 비율의 오일과 물의 에멀젼을 가지고 있다. 피부의 각질층 외층까지 잘 침투한다. 크림은 로션보다 두껍고 용기에서 꺼낼 때 모양이 유지된다.For example, creams are an emulsion of approximately equal proportions of oil and water. It penetrates well into the outer layer of the skin's stratum corneum. Creams are thicker than lotions and retain their shape when removed from the container.
또한, 본 발명의 조성물은 팩, 밴드 또는 패치 중 어느 하나에 포함될 수 있으며, 이에 제한되지 않는다.Additionally, the composition of the present invention may be included in any one of a pack, band, or patch, but is not limited thereto.
상기 팩은 국소형 패치, 시트타입, 거즈타입, 크림타입 및 젤타입 중 어느 하나의 형태일 수 있다.The pack may be in the form of any one of topical patch, sheet type, gauze type, cream type, and gel type.
상기 팩은 마스크팩, 손팩, 발팩, 종아리팩, 헤어팩, 허벅지팩, 복부팩, 옆구리팩, 팔뚝팩, 턱팩 및 목팩 중에서 선택되는 어느 하나일 수 있다.The pack may be any one selected from a mask pack, hand pack, foot pack, calf pack, hair pack, thigh pack, abdominal pack, side pack, forearm pack, chin pack, and neck pack.
본 발명의 조성물은 약학적 조성물 또는 화장료 조성물 중 어느 하나에 포함되는 것이 바람직하다.The composition of the present invention is preferably included in either a pharmaceutical composition or a cosmetic composition.
본 발명에서의 약학적 조성물은 정제, 캅셀제, 주사제, 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제 등을 포함하는 군에서 선택되는 제형일 수 있으나 이에 제한되지는 않는다.The pharmaceutical composition in the present invention is a dosage form selected from the group including tablets, capsules, injections, creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, cataplasma agents, etc. It may be possible, but it is not limited to this.
본 발명의 약학적 조성물은 제제시에 통상적으로 사용되는 약제학적으로 허용되는 담체, 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may further include pharmaceutically acceptable carriers, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. commonly used in preparation.
본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여, 점막 투여 및 점안 투여, 국소투여 등의 방식으로 투여할 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and in case of parenteral administration, it can be administered through methods such as intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, mucosal administration, eye drop administration, and local administration. It can be administered, but is not limited to this.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 섭취 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 바람직하게는, 본 발명의 약학적 조성물의 투여량은 성인 기준으로 0.0001-100 ㎎/kg(체중)일 수 있으나 이에 제한되는 것은 아니다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, ingested food, administration time, administration route, excretion rate, and reaction sensitivity. may be prescribed. Preferably, the dosage of the pharmaceutical composition of the present invention may be 0.0001-100 mg/kg (body weight) for adults, but is not limited thereto.
본 발명에 추가될 수 있는 적합한 성분의 선택은, 당업자에게 자명한 범위에서, 본 발명의 피부 외용제 조성물이 용액, 로션, 림, 연고, 겔, 폼 또는 경피 패치로 제형화 되는지 여부에 어느 정도 의존할 것이다.The selection of suitable ingredients that can be added to the present invention, as will be apparent to those skilled in the art, depends to some extent on whether the external skin composition of the present invention is formulated as a solution, lotion, cream, ointment, gel, foam, or transdermal patch. something to do.
예를 들어, 착색제(색소), 착향제(향료), 현탁화제, 유화제, 용해보조제, 안정제, 등장제, pH조절제, 점도조절제, 용제 등을 포함할 수 있다. 화장료 조성물에 통상적으로 부가되는 성분이나 함량 등은 당업자에게 자명할 것이다.For example, it may include colorants (pigments), flavoring agents (flavors), suspending agents, emulsifiers, solubilizers, stabilizers, isotonic agents, pH adjusters, viscosity adjusters, solvents, etc. The ingredients and contents commonly added to cosmetic compositions will be apparent to those skilled in the art.
한편, 본 발명의 화장료 조성물은 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 및 헤어스프레이 등을 포함하는 군에서 선택되는 제형일 수 있으나, 이에 제한되는 것은 아니다.On the other hand, the cosmetic composition of the present invention can be used as hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, hair Wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair dryer, hair preservation treatment, hair dye, hair waving agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer, It may be a formulation selected from the group including hair moisturizer, hair mousse, and hair spray, but is not limited thereto.
이하에서는 본 발명에 따른 조성물의 구체적인 실시예 및 실험예를 통해 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described in more detail through specific examples and experimental examples of the composition according to the present invention.
[실시예 1. 모란 뿌리 추출물의 제조][Example 1. Preparation of peony root extract]
건조된 모란 뿌리를 분쇄기를 이용하여 잘게 분쇄하여 분말화하였다. 모란 뿌리 분말과 70%에탄올을 혼합한 후, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 모란 뿌리 추출물을 수득하였다.The dried peony roots were finely ground using a grinder and powdered. After mixing peony root powder and 70% ethanol, an extraction solution was prepared for 3 hours at room temperature using a stirrer. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a peony root extract.
[실시예 2. 우엉 뿌리 추출물의 제조][Example 2. Preparation of burdock root extract]
건조된 우엉 뿌리를 분쇄기를 이용하여 잘게 분쇄하여 분말화하였다. 우엉 뿌리 분말과 70%에탄올을 혼합한 후, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 우엉 뿌리 추출물을 수득하였다.The dried burdock roots were finely ground using a grinder and powdered. After mixing burdock root powder and 70% ethanol, an extraction solution was prepared for 3 hours at room temperature using a stirrer. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a burdock root extract.
[실시예 3. 지황 뿌리 추출물의 제조][Example 3. Preparation of Rehmannia glutinosa root extract]
건조된 지황 뿌리를 분쇄기를 이용하여 잘게 분쇄하여 분말화하였다. 지황뿌리 분말과 70%에탄올을 혼합한 후, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 지황 뿌리 추출물을 수득하였다.The dried Rehmannia glutinosa roots were finely ground using a grinder and powdered. After mixing Rehmannia glutinosa root powder and 70% ethanol, an extraction solution was prepared for 3 hours at room temperature using a stirrer. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a Rehmannia glutinosa root extract.
[실시예 4. 참마 뿌리 추출물의 제조][Example 4. Preparation of yam root extract]
건조된 참마 뿌리를 분쇄기를 이용하여 잘게 분쇄하여 분말화하였다. 참마 뿌리 분말과 70%에탄올을 혼합한 후, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 참마 뿌리 추출물을 수득하였다.The dried yam roots were finely ground using a grinder and powdered. After mixing yam root powder and 70% ethanol, an extraction solution was prepared for 3 hours at room temperature using a stirrer. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a yam root extract.
[실시예 5. 천궁 뿌리 추출물의 제조][Example 5. Preparation of Cheonigung root extract]
건조된 천궁 뿌리를 분쇄기를 이용하여 잘게 분쇄하여 분말화하였다. 천궁 뿌리 분말과 70%에탄올을 혼합한 후, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 천궁 뿌리 추출물을 수득하였다.The dried roots were finely ground using a grinder and powdered. After mixing the root powder and 70% ethanol, an extraction solution was prepared for 3 hours at room temperature using a stirrer. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a root extract.
[실시예 6. 모란 뿌리 및 우엉 뿌리 혼합 추출물의 제조][Example 6. Preparation of mixed extract of peony root and burdock root]
건조된 모란 뿌리와 우엉 뿌리 분말을 각각 1:1의 비로 혼합하고 70%에탄올을 첨가한 뒤, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 모란 뿌리 및 우엉 뿌리 혼합 추출물을 수득하였다.Dried peony root and burdock root powder were mixed in a ratio of 1:1, 70% ethanol was added, and an extraction solution was prepared using a stirrer at room temperature for 3 hours. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a mixed extract of peony root and burdock root.
[실시예 7. 모란 뿌리, 우엉 뿌리 및 지황 뿌리 혼합 추출물의 제조][Example 7. Preparation of mixed extract of peony root, burdock root and Rehmannia root]
건조된 모란 뿌리, 우엉 뿌리 및 지황 뿌리 분말을 각각 1:1:1의 비로 혼합하고 70%에탄올을 첨가한 뒤, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 모란 뿌리 및 우엉 뿌리, 지황 뿌리 혼합 추출물을 수득하였다.Dried peony root, burdock root, and Rehmannia glutinosa root powder were mixed in a ratio of 1:1:1, respectively, 70% ethanol was added, and an extraction solution was prepared using a stirrer at room temperature for 3 hours. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a mixed extract of peony root, burdock root, and Rehmannia glutinosa root.
[실시예 8. 모란 뿌리, 우엉 뿌리, 지황 뿌리 및 참마 뿌리 혼합 추출물의 제조][Example 8. Preparation of mixed extract of peony root, burdock root, Rehmannia root and yam root]
건조된 모란 뿌리, 우엉 뿌리, 지황 뿌리 및 참마 뿌리 분말을 각각 1:1:1:1의 비로 혼합하고 70%에탄올을 첨가한 뒤, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 모란 뿌리 및 우엉 뿌리, 지황 뿌리, 참마 뿌리 혼합 추출물을 수득하였다.Dried peony root, burdock root, Rehmannia glutinosa root, and yam root powder were mixed in a ratio of 1:1:1:1, respectively, 70% ethanol was added, and an extraction solution was prepared using a stirrer at room temperature for 3 hours. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a mixed extract of peony root, burdock root, Rehmannia glutinosa root, and yam root.
[실시예 9. 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 혼합 추출물의 제조][Example 9. Preparation of mixed extracts of peony root, burdock root, Rehmannia glutinosa root, yam root and Aspergillus root]
건조된 모란 뿌리, 우엉 뿌리, 지황 뿌리, 참마 뿌리 및 천궁 뿌리 분말을 각각 1:1:1:1:1의 비로 혼합하고 70%에탄올을 첨가한 뒤, 교반기를 이용하여 상온에서 3시간 동안 추출 용액을 제조하였다. 부직포 여과지를 이용하여 추출 용액을 1차 여과한 뒤, 1차 여과액을 No. 5C 여과지를 이용해 감압여과 하였다. 이를 감압 농축하여 추출물 내 에탄올 성분을 완전히 제거함으로써 모란 뿌리 및 우엉 뿌리, 지황 뿌리, 참마 뿌리, 천궁 뿌리 혼합 추출물을 수득하였다.Mix dried peony root, burdock root, Rehmannia glutinosa root, yam root, and Aspergillus root powder in a ratio of 1:1:1:1:1, add 70% ethanol, and extract for 3 hours at room temperature using a stirrer. A solution was prepared. After primary filtration of the extraction solution using non-woven filter paper, the primary filtrate was filtered using no. It was filtered under reduced pressure using 5C filter paper. This was concentrated under reduced pressure to completely remove the ethanol component in the extract, thereby obtaining a mixed extract of peony root, burdock root, Rehmannia glutinosa root, yam root, and Aspergillus root.
[실험예 1 : 세포 내 활성산소종 생성 저해능 측정][Experimental Example 1: Measurement of inhibition ability to generate reactive oxygen species in cells]
인체 유래 각질형성세포(HaCaT)를 플레이트에서 24시간 배양한 뒤, 대조군(control) 및 실시예 1 내지 9를 처리하여 24시간 배양하였다. 각 처리구에 DCFH-DA를 처리하여 반응시킨 뒤, 과산화수소(H2O2)를 처리하여 산화를 유도하였다. 형광값을 측정하여 세포 내에서 발생하는 활성산소종(Reactive oxygen species; ROS)의 생성 저해능을 확인하였다. Human-derived keratinocytes (HaCaT) were cultured on a plate for 24 hours, then treated with the control and Examples 1 to 9 and cultured for 24 hours. Each treatment group was reacted with DCFH-DA and then treated with hydrogen peroxide (H 2 O 2 ) to induce oxidation. By measuring the fluorescence value, the ability to inhibit the production of reactive oxygen species (ROS) occurring within cells was confirmed.
도 1에 도시된 바와 같이, 실시예 1 내지 실시예 5에 비해 실시예 8 및 실시예 9의 활성산소종 저해능이 증가하며, 실시예 8에 비해 실시예 9의 활성산소종 저해능이 증가하는 것으로 확인되었다.As shown in Figure 1, the reactive oxygen species inhibition ability of Examples 8 and 9 increases compared to Examples 1 to 5, and the reactive oxygen species inhibition ability of Example 9 increases compared to Example 8. Confirmed.
[실험예 2 : 세포 내 산화질소 생성 저해능 측정][Experimental Example 2: Measurement of intracellular nitric oxide production inhibition ability]
마우스 유래 대식세포(Raw264.7)를 플레이트에서 24시간 배양한 뒤, 염증 반응 유도 물질인 리포폴리사카라이드(Lipopolysaccharide; LPS)와 함께 실시예 1 내지 9를 처리하여 24시간 배양하였다. 세포 배양액을 회수한 뒤, promega 社의 griess reagent system을 사용하여 반응시켰다. 흡광값을 측정하여 세포 내에서 발생하는 산화질소(Nitric oxide; NO)의 생성 저해능을 확인하였다. Mouse-derived macrophages (Raw264.7) were cultured on a plate for 24 hours, then treated with Examples 1 to 9 along with lipopolysaccharide (LPS), an inflammatory response-inducing substance, and cultured for 24 hours. After recovering the cell culture medium, it was reacted using Promega's Griess reagent system. By measuring the absorbance value, the ability to inhibit the production of nitric oxide (NO) occurring within cells was confirmed.
도 2에 도시된 바와 같이, 실시예 1 내지 실시예 5에 비해 실시예 8 및 실시예 9의 산화질소 생성 저해능이 증가하며, 실시예 8에 비해 실시예 9의 산화질소 생성 저해능이 증가하는 것으로 확인되었다.As shown in Figure 2, the ability to inhibit nitric oxide production in Examples 8 and 9 increases compared to Examples 1 to 5, and the ability to inhibit nitric oxide production in Example 9 increases compared to Example 8. Confirmed.
[실험예 3 : 전염증성 사이토카인 발현 억제 측정][Experimental Example 3: Measurement of inhibition of pro-inflammatory cytokine expression]
인체 유래 각질형성세포(HaCaT)를 플레이트에서 24시간 배양한 뒤, 염증 반응 유도 물질인 리포폴리사카라이드(Lipopolysaccharide; LPS)와 함께 실시예 1 내지 9를 처리하여 24시간 배양하였다. 세포를 회수하여 RNA를 분리한 뒤, RT-PCR을 진행하여 전염증성 사이토카인인 tumor necrosis factor-α(TNF-α) 및 interleukin-6(IL-6)의 유전자 발현량을 확인하였다. Human-derived keratinocytes (HaCaT) were cultured on a plate for 24 hours, then treated with Examples 1 to 9 together with lipopolysaccharide (LPS), an inflammatory response-inducing substance, and cultured for 24 hours. Cells were recovered, RNA was isolated, and RT-PCR was performed to confirm the gene expression levels of pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).
도 3에 도시된 바와 같이, 실시예 1 내지 실시예 5에 비해 실시예 8 및 실시예 9의 TNF-α 발현량이 낮으며, 실시예 8에 비해 실시예 9의 발현량이 더 낮은 것으로 확인되었다. As shown in Figure 3, the expression level of TNF-α in Examples 8 and 9 was lower than that in Examples 1 to 5, and the expression level of Example 9 was confirmed to be lower than that of Example 8.
또한 도 4에 도시된 바와 같이, 실시예 1 내지 실시예 5에 비해 실시예 8 및 실시예 9의 IL-6 발현량이 낮으며, 실시예 8에 비해 실시예 9의 발현량이 더 낮은 것으로 확인되었다.In addition, as shown in Figure 4, the expression level of IL-6 in Examples 8 and 9 was lower than that in Examples 1 to 5, and the expression level of Example 9 was confirmed to be lower than that in Example 8. .
[실험예 4 : 염증 유도형 효소 발현 억제 측정][Experimental Example 4: Measurement of inhibition of inflammation-induced enzyme expression]
인체 유래 각질형성세포(HaCaT)를 플레이트에서 24시간 배양한 뒤, 염증 반응 유도 물질인 리포폴리사카라이드(Lipopolysaccharide; LPS)와 함께 실시예 1 내지 9를 처리하여 24시간 배양하였다. 세포를 회수하여 RNA를 분리한 뒤, RT-PCR을 진행하여 염증 반응에 관여하는 효소인 cyclooxygenase-2(COX-2)의 유전자 발현량을 확인하였다. Human-derived keratinocytes (HaCaT) were cultured on a plate for 24 hours, then treated with Examples 1 to 9 together with lipopolysaccharide (LPS), an inflammatory response-inducing substance, and cultured for 24 hours. The cells were recovered, RNA was isolated, and RT-PCR was performed to confirm the gene expression level of cyclooxygenase-2 (COX-2), an enzyme involved in the inflammatory response.
도 5에 도시된 바와 같이, 실시예 1 내지 실시예 5에 비해 실시예 8 및 실시예 9의 COX-2 발현량이 낮으며, 실시예 8에 비해 실시예 9의 발현량이 더 낮은 것으로 확인되었다.As shown in Figure 5, the expression level of COX-2 in Examples 8 and 9 was lower than that in Examples 1 to 5, and the expression level of Example 9 was confirmed to be lower than that in Example 8.
이상에서 본 발명의 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고, 청구범위에 기재된 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 다양한 수정 및 변형이 가능하다는 것은 당 기술분야의 통상의 지식을 가진 자에게는 자명할 것이다.Although the embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and variations are possible without departing from the technical spirit of the present invention as set forth in the claims. This will be self-evident to those with ordinary knowledge in the field.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230008928A KR102606838B1 (en) | 2023-01-20 | 2023-01-20 | Antioxidative and antiinflammatory compostion comprising the extract of plant root |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230008928A KR102606838B1 (en) | 2023-01-20 | 2023-01-20 | Antioxidative and antiinflammatory compostion comprising the extract of plant root |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102606838B1 true KR102606838B1 (en) | 2023-11-29 |
Family
ID=88969351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230008928A KR102606838B1 (en) | 2023-01-20 | 2023-01-20 | Antioxidative and antiinflammatory compostion comprising the extract of plant root |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102606838B1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09110710A (en) * | 1995-10-24 | 1997-04-28 | Ichimaru Pharcos Co Ltd | Dermal preparation for external use and bathing agent |
KR20110134719A (en) * | 2010-06-09 | 2011-12-15 | (주)파이토니아 | Cosmetic composition and composition of skin external application |
KR101127156B1 (en) | 2009-08-14 | 2012-06-13 | 주식회사 래디안 | Cosmetic composition containing 2,4-dihydroxyacetophenone or the extract of cynanchum atratum bunge. comprising 2,4-dihydroxyacetophenone with the usage of skin-irritation alleviation |
KR101309172B1 (en) | 2005-06-29 | 2013-09-17 | 주식회사 엘지생활건강 | Composition for preventing from inflammation |
KR101397160B1 (en) | 2012-08-10 | 2014-05-20 | 주식회사 래디안 | Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance |
KR20160003920A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts |
KR20170077980A (en) * | 2015-12-29 | 2017-07-07 | 김수현 | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. |
KR101768870B1 (en) | 2015-04-13 | 2017-08-17 | 주식회사 래디안 | Cosmetic composition and pharmaceutical composition with sinapic acid or the extract of cynanchum atratum for wound healing |
KR102218985B1 (en) * | 2021-01-07 | 2021-02-23 | (주)티엔씨인터내셔널 | Method for extracting saponins and cosmetic composition containing the extracted saponin using the same method with antioxidation and antiaging |
-
2023
- 2023-01-20 KR KR1020230008928A patent/KR102606838B1/en active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09110710A (en) * | 1995-10-24 | 1997-04-28 | Ichimaru Pharcos Co Ltd | Dermal preparation for external use and bathing agent |
KR101309172B1 (en) | 2005-06-29 | 2013-09-17 | 주식회사 엘지생활건강 | Composition for preventing from inflammation |
KR101127156B1 (en) | 2009-08-14 | 2012-06-13 | 주식회사 래디안 | Cosmetic composition containing 2,4-dihydroxyacetophenone or the extract of cynanchum atratum bunge. comprising 2,4-dihydroxyacetophenone with the usage of skin-irritation alleviation |
KR20110134719A (en) * | 2010-06-09 | 2011-12-15 | (주)파이토니아 | Cosmetic composition and composition of skin external application |
KR101397160B1 (en) | 2012-08-10 | 2014-05-20 | 주식회사 래디안 | Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance |
KR20160003920A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts |
KR101768870B1 (en) | 2015-04-13 | 2017-08-17 | 주식회사 래디안 | Cosmetic composition and pharmaceutical composition with sinapic acid or the extract of cynanchum atratum for wound healing |
KR20170077980A (en) * | 2015-12-29 | 2017-07-07 | 김수현 | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. |
KR102218985B1 (en) * | 2021-01-07 | 2021-02-23 | (주)티엔씨인터내셔널 | Method for extracting saponins and cosmetic composition containing the extracted saponin using the same method with antioxidation and antiaging |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102212305B1 (en) | A cosmetic composition comprising plant extract as active ingredient, and a preparation method of thereof | |
CN111093621A (en) | Cosmetic composition containing dendrobium officinale flower extract | |
KR101626437B1 (en) | Cosmetic composition for improving skin inflammation or reducing skin irritation | |
KR101829892B1 (en) | A cosmetic composition comprising fraxinus rhynchophylla extract and calystegia soldanella extract | |
KR101073678B1 (en) | Shampoo composition using medical herbs and manufacturing method thereof | |
US20130101537A1 (en) | Skin-whitening composition containing extracts from trees including paper mulberry | |
KR20190028996A (en) | Cosmetic composition for protecting skin from UV which comprises extract of bitter ground, persimmon leaf and ceramium kondoi | |
KR100886743B1 (en) | Composition for skin whitening or promoting hair growth comprising gypenoside | |
KR101829891B1 (en) | A cosmetic composition comprising osmanthus asiaticus extract and clematis apiifolia extract | |
KR20170133560A (en) | A cosmetic composition for scalp and hair improvement comprising multiple extract of combined medicinal herbs | |
KR101582971B1 (en) | Cosmetic composition containing extract of Sambucus williamsii var. coreana and Clematis mandshurica Rupr for improving skin wrinkle | |
KR102606838B1 (en) | Antioxidative and antiinflammatory compostion comprising the extract of plant root | |
KR102168536B1 (en) | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts | |
KR101213531B1 (en) | Cosmetic composition for preventing skin aging | |
KR20100011176A (en) | Natural and oriental herbs complex with anti-hairloss and hair growth stimulating effects | |
KR100777542B1 (en) | Anti-dandruff hair-care cosmetic composition | |
KR20170107943A (en) | Skin Whitening Cosmetic Composition Containing Extracts of Wikstroemia trichotoma | |
KR20090107146A (en) | Cosmetic Composition For Stimulating the Blood Circulation and For Improving the Skin Color Containing Plant Complex Extracts | |
KR20180137151A (en) | Cosmetic composition for preventing photo aging comprising Curcuma longa Linne leaf and Hibiscus manihot extracts | |
KR20140103633A (en) | Cosmetic composition containing extract of Bambusoideae and Reynoutria japonica for anti-wrinkle or anti-aging | |
KR101592084B1 (en) | Cosmetic composition comprising the extract of plant | |
KR20170136969A (en) | Method for preparing natural extract using sugars | |
KR20130136753A (en) | Cosmetic composition comprising cercis chinensis or reynoutria japonica for. elata extract for skin whitening | |
KR102467403B1 (en) | Composition for preventing hair loss and promoting hair growth and method for manufacturing thereof | |
KR102119823B1 (en) | A cosmetic composition comprising morus bombycis extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |